This paper describes pharmacokinetic analyses of the monoamine-oxidase-B (MAO-B) radiotracer [18F](S)-(2-methylpyrid-5-yl)-6-[(3-fluoro-2-hydroxy)propoxy]quinoline ([18F]SMBT-1) for positron emission tomography (PET) brain imaging. Brain MAO-B expression is widespread, predominantly within astrocytes. Reactive astrogliosis in response to neurodegenerative disease pathology is associated with MAO-B overexpression. Fourteen elderly subjects (8 control, 5 mild cognitive impairment, 1 Alzheimer’s disease) with amyloid ([11C]PiB) and tau ([18F]flortaucipir) imaging assessments underwent dynamic [18F]SMBT-1 PET imaging with arterial input function determination. [18F]SMBT-1 showed high brain uptake and a retention pattern consistent with the known MAO-B distribution. A two-tissue compartment (2TC) model where the K1/k2 ratio was fixed to a whole brain value best described [18F]SMBT-1 kinetics. The 2TC total volume of distribution (VT) was well identified and highly correlated (r2∼0.8) with post-mortem MAO-B indices. Cerebellar grey matter (CGM) showed the lowest mean VT of any region and is considered the optimal pseudo-reference region. Simplified analysis methods including reference tissue models, non-compartmental models, and standard uptake value ratios (SUVR) agreed with 2TC outcomes (r2 > 0.9) but with varying bias. We found the CGM-normalized 70–90 min SUVR to be highly correlated (r2 = 0.93) with the 2TC distribution volume ratio (DVR) with acceptable bias (∼10%), representing a practical alternative for [18F]SMBT-1 analyses.
ShihJCChenKRiddMJ.Monoamine oxidase: from genes to behavior. Annu Rev Neurosci1999;
22: 197–217.
2.
TiptonKF.The sub-mitochondrial localization of monoamine oxidase in rat liver and brain. Biochim Biophys Acta1967;
135: 910–920.
3.
TongJMeyerJHFurukawaY, et al.
Distribution of monoamine oxidase proteins in human brain: implications for brain imaging studies. J Cereb Blood Flow Metab2013;
33: 863–871.
4.
FowlerCJWibergAOrelandL, et al.
The effect of age on the activity and molecular properties of human brain monoamine oxidase. J Neural Transm1980;
49: 1–20.
5.
EkblomJJossanSSBergströmM, et al.
Monoamine oxidase-B in astrocytes. Glia1993;
8: 122–132.
6.
AciogluCLiLElkabesS.Contribution of astrocytes to neuropathology of neurodegenerative diseases. Brain Res2021;
1758: 147291.
7.
KumarAFontanaICNordbergA.Reactive astrogliosis: a friend or foe in the pathogenesis of alzheimer's disease. J Neurochem2023;
164: 309–324.
8.
GulyásBPavlovaEKásaP, et al.
Activated MAO-B in the brain of Alzheimer patients, demonstrated by [11C]-L-deprenyl using whole hemisphere autoradiography. Neurochem Int2011;
58: 60–68.
9.
SauraJLuqueJMCesuraAM, et al.
Increased monoamine oxidase B activity in plaque-associated astrocytes of Alzheimer brains revealed by quantitative enzyme radioautography. Neuroscience1994;
62: 15–30.
10.
KovacsGGXieSXRobinsonJL, et al.
Sequential stages and distribution patterns of aging-related tau astrogliopathy (ARTAG) in the human brain. Acta Neuropathol Commun2018;
6: 50.
11.
Amador-OrtizCAhmedZZehrC, et al.
Hippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration. Acta Neuropathol2007;
113: 245–252.
12.
RadfordRAMorschMRaynerSL, et al.
The established and emerging roles of astrocytes and microglia in amyotrophic lateral sclerosis and frontotemporal dementia. Front Cell Neurosci2015;
9: 414.
13.
EnglerHNennesmoIKumlienE, et al.
Imaging astrocytosis with PET in Creutzfeldt-Jakob disease: case report with histopathological findings. Int J Clin Exp Med2012;
5: 201–207.
14.
BoothHDEHirstWDWade-MartinsR.The role of astrocyte dysfunction in Parkinson's disease pathogenesis. Trends Neurosci2017;
40: 358–370.
15.
FowlerJSMacGregorRRWolfAP, et al.
Mapping human brain monoamine oxidase a and B with 11C-labeled suicide inactivators and PET. Science1987;
235: 481–485.
16.
FowlerJSWangGJLoganJ, et al.
Selective reduction of radiotracer trapping by deuterium substitution: comparison of carbon-11-L-deprenyl and carbon-11-deprenyl-D2 for MAO B mapping. J Nucl Med1995;
36: 1255–1262.
17.
SantilloAFGambiniJPLannfeltL, et al.
In vivo imaging of astrocytosis in Alzheimer's disease: an 11C-L-deuteriodeprenyl and PIB PET study. Eur J Nucl Med Mol Imaging2011;
38: 2202–2208.
18.
CarterSFChiotisKNordbergA, et al.
Longitudinal association between astrocyte function and glucose metabolism in autosomal dominant Alzheimer's disease. Eur J Nucl Med Mol Imaging2019;
46: 348–356.
19.
CarterSFSchöllMAlmkvistO, et al.
Evidence for astrocytosis in prodromal Alzheimer disease provided by 11C-deuterium-L-deprenyl: a multitracer PET paradigm combining 11C-Pittsburgh compound B and 18F-FDG. J Nucl Med2012;
53: 37–46.
20.
ReynoldsGPElsworthJDBlauK, et al.
Deprenyl is metabolized to methamphetamine and amphetamine in man. Br J Clin Pharmacol1978;
6: 542–544.
21.
SabaWValetteHPeyronneauMA, et al.
[(11)C]SL25.1188, a new reversible radioligand to study the monoamine oxidase type B with PET: preclinical characterisation in nonhuman primate. Synapse2010;
64: 61–69.
22.
RusjanPMWilsonAAMilerL, et al.
Kinetic modeling of the monoamine oxidase B radioligand [11C]SL25.1188 in human brain with high-resolution positron emission tomography. J Cereb Blood Flow Metab2014;
34: 883–889.
23.
NgKPPascoalTAMathotaarachchiS, et al.
Monoamine oxidase B inhibitor, selegiline, reduces (18)F-THK5351 uptake in the human brain. Alzheimers Res Ther2017;
9: 25.
24.
IshibashiKMiuraYHirataK, et al.
18F-THK5351 PET can identify astrogliosis in multiple sclerosis plaques. Clin Nucl Med2020;
45: e98–e100.
25.
TagoTToyoharaJSengokuR, et al.
Monoamine oxidase B binding of 18F-THK5351 to visualize glioblastoma and associated gliosis: an Autopsy-Confirmed case. Clin Nucl Med2019;
44: 507–509.
26.
TakamiYYamamotoYNorikaneT, et al.
18F-THK5351 PET can identify lesions of acute traumatic brain injury. Clin Nucl Med2020;
45: e491–e492.
27.
HaradaRHayakawaYEzuraM, et al.
(18)F-SMBT-1: a selective and reversible PET tracer for monoamine oxidase-B imaging. J Nucl Med2021;
62: 253–258.
28.
VillemagneVLHaradaRDoréV, et al.
First-in-humans evaluation of (18)F-SMBT-1, a novel (18)F-labeled monoamine oxidase-B PET tracer for imaging reactive astrogliosis. J Nucl Med2022;
63: 1551–1559.
29.
GandelmanMSBaldwinRMZoghbiSS, et al.
Evaluation of ultrafiltration for the free-fraction determination of single photon emission computed tomography (SPECT) radiotracers: beta-CIT, IBF, and iomazenil. J Pharm Sci1994;
83: 1014–1019.
30.
SomvanshiPR, andVenkateshKV, et al. Hill equation. In: DubitzkyWWolkenhauerOChoK-H, (eds) Encyclopedia of systems biology.
New York, NY:
Springer New York, 2013, pp. 892–895.
31.
WatabeHChanningMADerMG, et al.
Kinetic analysis of the 5-HT2A ligand [11C]MDL 100,907. J Cereb Blood Flow Metab2000;
20: 899–909.
32.
JakobyBWBercierYContiM, et al.
Physical and clinical performance of the mCT time-of-flight PET/CT scanner. Phys Med Biol2011;
56: 2375–2389.
33.
SnitzBETudorascuDLYuZ, et al.
Associations between NIH toolbox cognition battery and in vivo brain amyloid and tau pathology in non-demented older adults. Alzheimers Dement (Amst)2020;
12: e12018.
34.
BourgeatPDoréVFrippJ, AIBL research groupet al.
Implementing the centiloid transformation for (11)C-PiB and β-amyloid (18)F-PET tracers using CapAIBL. Neuroimage2018;
183: 387–393.
35.
SullivanKJLiuAChangCH, et al.
Alzheimer's disease pathology in a community-based sample of older adults without dementia: the MYHAT neuroimaging study. Brain Imaging Behav2021;
15: 1355–1363.
36.
GogolaALoprestiBJTudorascuD, et al.
Biostatistical estimation of tau threshold hallmarks (BETTH) algorithm for human tau PET imaging studies. J Nucl Med2023;
64: 1798–1805.
InnisRBCunninghamVJDelforgeJ, et al.
Consensus nomenclature for in vivo imaging of reversibly binding radioligands. J Cereb Blood Flow Metab2007;
27: 1533–1539.
39.
SauraJBleuelZUlrichJ, et al.
Molecular neuroanatomy of human monoamine oxidases A and B revealed by quantitative enzyme radioautography and in situ hybridization histochemistry. Neuroscience1996;
70: 755–774.
40.
LeendersKLPeraniDLammertsmaAA, et al.
Cerebral blood flow, blood volume and oxygen utilization. Normal values and effect of age. Brain1990;
113 (Pt 1): 27–47.
41.
LoganJFowlerJSVolkowND, et al.
Graphical analysis of reversible radioligand binding from time-activity measurements applied to [N-11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab1990;
10: 740–747.
42.
IchiseMToyamaHInnisRB, et al.
Strategies to improve neuroreceptor parameter estimation by linear regression analysis. J Cereb Blood Flow Metab2002;
22: 1271–1281.
43.
SalinasCASearleGEGunnRN.The simplified reference tissue model: model assumption violations and their impact on binding potential. J Cereb Blood Flow Metab2015;
35: 304–311.
44.
LoganJFowlerJSVolkowND, et al.
Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab1996;
16: 834–840.
45.
IchiseMLiowJSLuJQ, et al.
Linearized reference tissue parametric imaging methods: application to [11C]DASB positron emission tomography studies of the serotonin transporter in human brain. J Cereb Blood Flow Metab2003;
23: 1096–1112.
46.
LammertsmaAAHumeSP.Simplified reference tissue model for PET receptor studies. Neuroimage1996;
4: 153–158.
47.
LoprestiBJKlunkWEMathisCA, et al.
Simplified quantification of Pittsburgh compound B amyloid imaging PET studies: a comparative analysis. J Nucl Med2005;
46: 1959–1972.
48.
ShcherbininSSchwarzAJJoshiA, et al.
Kinetics of the tau PET tracer 18F-AV-1451 (T807) in subjects with normal cognitive function, mild cognitive impairment, and Alzheimer disease. J Nucl Med2016;
57: 1535–1542.
49.
PascoalTAShinMKangMS, et al.
In vivo quantification of neurofibrillary tangles with [(18)F]MK-6240. Alzheimers Res Ther2018;
10: 74.
50.
AkaikeH.A new look at the statistical model identification. IEEE Trans Automat Contr1974;
19: 716–723.
51.
SugiuraN.Further analysis of the data by Akaike's information criterion and the finite corrections. Commun Stat – Theory Methods1978;
7: 13–26.
52.
BenjaminiYHochbergY.Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc Ser B (Methodol)1995;
57: 289–300.
53.
HaradaRFurumotoSTagoT, et al.
Characterization of the radiolabeled metabolite of tau PET tracer (18)F-THK5351. Eur J Nucl Med Mol Imaging2016;
43: 2211–2218.
54.
HaradaRShimizuYDuY, et al.
The role of chirality of [(18)F]SMBT-1 in imaging of monoamine oxidase-B. ACS Chem Neurosci2022;
13: 322–329.
55.
ParseyRVSlifsteinMHwangDR, et al.
Validation and reproducibility of measurement of 5-HT1A receptor parameters with [carbonyl-11C]WAY-100635 in humans: comparison of arterial and reference tissue input functions. J Cereb Blood Flow Metab2000;
20: 1111–1133.
56.
CunninghamVJRabinerEASlifsteinM, et al.
Measuring drug occupancy in the absence of a reference region: the Lassen plot re-visited. J Cereb Blood Flow Metab2010;
30: 46–50.
57.
BuchertRDirksMSchützeC, et al.
Reliable quantification of (18)F-GE-180 PET neuroinflammation studies using an individually scaled population-based input function or late tissue-to-blood ratio. Eur J Nucl Med Mol Imaging2020;
47: 2887–2900.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
